Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Recruiting · Phase 2 · NCT06839053
Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mantle Cell Lymphoma, Refractory Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
At a glance
- Research payments reported, 2025
- $96,053
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 30
About the trial
- Sponsor
- Fred Hutchinson Cancer Center (with BeOne Medicines)
- Tested
- Biospecimen Collection (procedure), Bone Marrow Biopsy (procedure), Computed Tomography (procedure), Gastrointestinal Endoscopy (procedure), Rituximab (biological), Sonrotoclax (drug), Zanubrutinib (drug)
- Dates
- Started 2025-06-02; completion 2032-07-01
- Results posted
- Not yet
This phase II trial studies the side effects of an escalated ramp-up of sonrotoclax following initial debulking with zanubrutinib or rituximab in treating patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL) that is newly diagnosed, has come back after a period of improvement (relapsed) or does not respond to treatment (refractory). Rituximab is a monoclonal antibody that binds to a protein called CD20, which is found on B-cells, and may kill tumor cells. Zanubrutinib may stop the growth of tumor cells by blocking a protein called Bruton's tyrosine kinase (BTK), which is needed for tumor cell growth. Sonrotoclax works by blocki…
From ClinicalTrials.gov, last updated 2026-10-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines USA, Inc. reported $96,053 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Fred Hutchinson Cancer Center $96,053
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.